06.26.18 Reno, NV Cyrcadia Health Announces New Medical Advisor, Kevin Buckman, M.D.

Dr. Buckman has over 35 years of Emergency Medicine Experience and is currently a Physician with Team Health in Lodi, CA. He has served as Medical Director or Associate Medical Director in hospitals and institutions for over 20 years and has over 40 years of clinical experience. He has served as Medical Director in the Emergency Department and as a member of the Executive Committee for six years at St. Dominic’s Hospital in Manteca, California. He also served as Director of the Emergency Department at Navy Lemoore Hospital in California. Dr. Buckman is the author of many books, including Find & Stop Breast Cancer, The Metabolic Origin of Cancer. He was a Fellow in the American Association of Integrated Medicine, and is a Board Certified Medical Review Officer. He has been certified with the National Registry of Certified Medical Examiners since 2014. His other specialties include: Internal Medicine, Forensic Medicine, Medical Acupuncture. He has presented research, published articles and books in the field of medicine, and given lectures at numerous hospitals and at International Medical Conferences. He has received Post Graduate Training at Stanford University School of Business and attended seminars with the Securities Exchange Institute. He has numerous Medical Publications, including topics on breast cancer, oncology, and other topics. He was the first US Physician to be accepted into the European Group for Breast Cancer Screening after his research in this field was accepted for publication and presentation at their international conference in Cyprus. During the last 30 years he has worked to advance a number of medical technologies with a focus on Non-Harmful early detection of disease,...

Reno, NV June 12, 2018, Cyrcadia, Inc. New Member of Board of Directors

Cyrcadia, Inc. is pleased to announce the addition of Ed Wertzberger to the Board of Directors as we continue to focus on implementation of our aggressive growth strategy and Go-To-Market plan. Jim Holmes, Chairman of the Board, says, “We are pleased to have an executive join our Board who possesses extensive leadership and global experience. We are confident Ed’s 35 years of leadership, financial management and operational consulting and governance experience will bring a fresh perspective and insights as we implement our product plans.” Matt Benardis, CEO, added “We have already seen impact from Ed’s involvement as we review and negotiate company contracts and develop corporate policies and governance”. Ed’s leadership background includes management experience in global leadership roles with the “Big Four” accounting firms, consulting for Fortune 500 companies, led hospital transformations, and is the co-founder of a boutique management consulting firm. In addition, Ed’s experience includes over 20 years as a partner with Arthur Andersen and Deloitte, Big Four firms. He has led global strategy planning and implementation initiatives, business transformation and customer loyalty programs. He has been a member of numerous leadership and governance teams to align operations and implementation teams. He has served on numerous not-for-profit organization Board’s, including as President for several. Ed’s educational background includes a Bachelor of Business Administration – Accounting from the University of Iowa and he obtained his CPA in 1976. Next steps: Announce new product and new chief medical...

Reno, NV May 29, 2018, Cyrcadia Health “B” Warrant Acceleration Option

Based on 2018 Go-To-Market plans, investment infusion is paramount in keeping on track and maintaining our accelerated pace. Our stakeholders have been essential in supporting our march to bring the most advanced Breast Health product to market. For those stakeholders holding “B” warrants, the warrants will expire December 31, 2018, meaning conversion to shares in the company will no longer be an option, losing all value. Accordingly, we are offering a “B” Warrant acceleration option effective now until June 30, 2018 allowing our stakeholders to continue to be part of and support the next phase of company operations: “B” Warrant Conversion price: $0.50 per warrant. “E” Warrant Addition: for each “B” Warrant converted to shares on or before June 30, 2018, Cyrcadia, Inc. will offer one (1) “E” warrant for each “B” Warrant converted, with an exercise date of December 31, 2019 at $1.00 per warrant. “This acceleration option allows our warrant holders to extend their expiration date while supporting our plans with the investment infusion at this time”, says Jim Holmes, CFO. “Warrant holders should note that new investors are investing at $1.00 per share and this acceleration option extends the time to participate in the increased value of the company as we achieve our market and sales milestones”, adds Holmes Direct inquiries to Jim Holmes at 775-852-3222 or email to...

Reno, NV May 21, 2018, Key Partnerships for Cyrcadia Health

Three key partner relationships are in place to bring “Best of Breed” subject matter experts into the Cyrcadia Health, Go-To-Market sales launch plan: Consumer Marketing: Dupuis Marketing, Chicago: branding, packaging, social media advertising, and user experience design. “We develop and create business opportunities that establish new meaning for people–digging for deeper truths beyond commonly leveraged insights, evolving brand relevance and creating breakthrough products and services. We translate our clients’ business challenges into sustainable, responsible growth opportunities.” Clinical Marketing: Life Sciences Strategy Group, San Jose: product visualization, product and market strategy. “Our approach employs best practices to align strategy with portfolio management and product development and commercialization processes. This integrated solution results in alignment of near, short and long–term planning cycles and development of strong and actionable marketing/brand, portfolio, new product, licensing and managed market strategies.” Nerdy Dragon, Boise: IT infrastructure and web site management. “Nerdy Dragon is a connector and collaborative agency focused on digital asset design, production, and management. We deliver for clients – consistently, reliably, with world class quality and super-reasonable turnaround. We have designed and developed hundreds of web and app experiences since 2009. We are a team of over 300, located on 5 continents, working tirelessly to execute on digital projects – making, doing, connecting, and thriving. We have team members located in the US, South America, Australia, Asia, and Africa.” “Principals of these companies have been involved with Cyrcadia Health for a number of years and have a deep understanding of our value proposition to bring significant value to our Go-To-Market launch,” says Matt Benardis, CEO. “Their depth of experience in our markets means...

May 14, 2018, Reno, NV. Artificial Intelligence Advancements

New discoveries have been achieved with our artificial intelligence (AI) algorithms. Recalling the foundational basis for the Cyrcadia Health intellectual property and patent filings is five algorithms that analyze tissue temperature and circadian body rhythm disruptions over a time period (dynamic) to identify tissue abnormalities. “Recently, our AI software scientists have made new discoveries that will bring additional value to our users who want to understand their health condition”, says Matt Benardis, CEO. Advanced data analysis and formula modification has achieved three goals: The science of ability to locate a tissue liesion abnormality location has now been verified. This means a doctor will know where to start more advanced therapies. Location is significant, as this will allow the physician to focus on a specific area for further investigation. With additional data from our clinical studies, we can advance our tissue knowledge without having to re-engineer our device and sensors. A new Wellness score can be computed based on metabolic patterns that can be used to begin tracking behaviors on the basis of clinical trial data. Wear time can now be as little as two hours. Analysis of datasets has detected the same statistical probability in a two hour dataset as in an 8 hour dataset. This means the Circadian disruption is perpetuated throughout the circadian cycle, leaving a detectable “signature”. This signature means the metabolic behavior can be identified for continued observation. Our four clinical trials continue to show the same successful outcomes through our analysis of this thermo-circadian disruption caused by abnormal breast tissue (via morphological and endocrine factors) and the resulting dynamic temperature patterns. In addition, we...